Multiple Sclerosis Clinical Trial

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Summary

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
Inadequate response to anticholinergic medication used to treat overactive bladder

Exclusion Criteria:

History of evidence of pelvic or urologic abnormality
Previous or current diagnosis of bladder or prostate cancer
Urinary tract infection at time of enrollment

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

416

Study ID:

NCT00311376

Recruitment Status:

Completed

Sponsor:

Allergan

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


Royal Oak Michigan, , United States

Randwick New South Wales, , Australia

Innsbruck , , Austria

Gent , , Belgium

Sherbrooke , , Canada

Ostrava , , Czech Republic

Garches , , France

Halle (Saale) , , Germany

Christchurch , , New Zealand

Wroclaw , , Poland

Moscow , , Russian Federation

Martin , , Slovakia

Lviv , , Ukraine

London , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

416

Study ID:

NCT00311376

Recruitment Status:

Completed

Sponsor:


Allergan

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider